New Potent DOT1L Inhibitors for


Journal

ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073

Informations de publication

Date de publication:
12 Dec 2019
Historique:
received: 01 10 2019
accepted: 25 11 2019
entrez: 21 12 2019
pubmed: 21 12 2019
medline: 21 12 2019
Statut: epublish

Résumé

In MLL-rearranged cancer cells, disruptor of telomeric silencing 1-like protein (DOT1L) is aberrantly recruited to ectopic loci leading to local hypermethylation of H3K79 and consequently misexpression of leukemogenic genes. A structure-guided optimization of a HTS hit led to the discovery of DOT1L inhibitors with subnanomolar potency, allowing testing of the therapeutic principle of DOT1L inhibition in a preclinical mouse tumor xenograft model. Compounds displaying good exposure in mouse and nanomolar inhibition of target gene expression in cells were obtained and tested in vivo.

Identifiants

pubmed: 31857842
doi: 10.1021/acsmedchemlett.9b00452
pmc: PMC6912874
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1655-1660

Informations de copyright

Copyright © 2019 American Chemical Society.

Déclaration de conflit d'intérêts

The authors declare the following competing financial interest(s): Authors are shareholders of Novartis and/or employees of Novartis.

Références

Cold Spring Harb Perspect Med. 2017 Nov 1;7(11):null
pubmed: 28242784
Cancer Cell. 2011 Jul 12;20(1):66-78
pubmed: 21741597
Blood. 2018 Jun 14;131(24):2661-2669
pubmed: 29724899
Cancer Cell. 2011 Jul 12;20(1):53-65
pubmed: 21741596
Biochem Pharmacol. 2018 Jan;147:183-190
pubmed: 28943239
Biomolecules. 2018 Feb 27;8(1):
pubmed: 29495487
Haematologica. 2009 Jul;94(7):984-93
pubmed: 19535349
Blood. 2013 Aug 8;122(6):1017-25
pubmed: 23801631
ACS Med Chem Lett. 2016 Jun 06;7(8):730-4
pubmed: 27563394
ACS Med Chem Lett. 2016 Jun 01;7(8):735-40
pubmed: 27563395
Cancer Cell. 2008 Nov 4;14(5):355-68
pubmed: 18977325
Trends Immunol. 2012 Nov;33(11):563-70
pubmed: 22867873
Biopharm Drug Dispos. 2014 May;35(4):237-52
pubmed: 24415392
ACS Med Chem Lett. 2017 Feb 14;8(3):338-343
pubmed: 28337327
Annu Rev Pathol. 2012;7:283-301
pubmed: 22017583

Auteurs

Frédéric Stauffer (F)

Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland.

Andreas Weiss (A)

Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland.

Clemens Scheufler (C)

Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland.

Henrik Möbitz (H)

Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland.

Christian Ragot (C)

Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland.

Kim S Beyer (KS)

Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland.

Keith Calkins (K)

Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland.

Daniel Guthy (D)

Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland.

Michael Kiffe (M)

Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland.

Bernard Van Eerdenbrugh (B)

Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland.

Ralph Tiedt (R)

Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland.

Christoph Gaul (C)

Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland.

Classifications MeSH